JamesPDeanMDPhD

PubMed

• 67 citations
  Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
  Constantine S Tam, John N Allan, Tanya Siddiqi, Thomas J Kipps, Ryan Jacobs, Stephen Opat, Paul M Barr, Alessandra Tedeschi, Livio Trentin, Rajat Bannerji, Sharon Jack...> ;Blood. 2022 Jun 2
• Outcomes of coronavirus disease 2019 (COVID-19) and risk factors associated with severe COVID-19 in patients with mature B-cell non-Hodgkin lymphomas: A US electronic ...
  Xiaomeng Yue, David Hallett, Yangyang Liu, Elisa Basa, Annie McNeill, James P Dean> ;European Journal of Haematology. 2023 Feb 1
• 42 citations
  First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumabchlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMI...
  Carol Moreno, Richard Greil, Fatih Demirkan, Alessandra Tedeschi, Bertrand Anz, Loree Larratt, Martin Simkovic, Jan Novak, Vladimir Strugov, Devinder Gill, John G Grib...> ;Haematologica. 2022 Sep 1
• 25 citations
  Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
  John N Allan, Tait Shanafelt, Carol Moreno, Susan M O'Brien, Jianling Li, Gabriel Krigsfeld, James P Dean, Inhye E Ahn, Adrian Wiestner> ;British Journal of Haematology. 2022 Feb 1
• 82 citations
  Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized...
  William G. Wierda, John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Stephen Opat, Alessandra Tedeschi, Xavier C. Badoux, Bryone J. Kuss, Sharon Jackson, Carol Moreno, Ry...> ;Journal of Clinical Oncology. 2021 Oct 7
• 4 citations
  Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
  Jennifer A. Woyach, Alessandra Tedeschi, Talha Munir, Tanya Siddiqi, Peter Hillmen, John C. Byrd, Paolo Ghia, Stephen P. Mulligan, Sandra Dai, Carlos I. Amaya-Chanaga,...> ;Leukemia & Lymphoma. 2021 Aug 13
• 78 citations
  Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies
  Steven Coutre, John C. Byrd, Peter Hillmen, Jacqueline C. Barrientos, Paul M. Barr, Stephen Devereux, Tadeusz Robak, Thomas J. Kipps, Anna Schuh, Carol Moreno, Richard...> ;Blood Advances. 2019 Jun 25
• 18 citations
  Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia.
  Isabelle G. Solman, Lisa K. Blum, Jan A. Burger, Thomas J. Kipps, James P. Dean, Danelle F. James, Ann Mongan> ;Leukemia Research. 2021 Feb 5
• 57 citations
  Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model
  Inhye E. Ahn, Xin Tian, David Ipe, Mei Cheng, Maher Albitar, L. Claire Tsao, Lei Zhang, Wanlong Ma, Sarah E. M. Herman, Erika M Gaglione, Susan Soto, James P. Dean> ;Journal of Clinical Oncology. 2021 Feb 20
• 38 citations
  Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia.
  Isabelle G. Solman, Lisa K. Blum, Hana Y. Hoh, Thomas J. Kipps, Jan A. Burger, Jacqueline C. Barrientos, Susan O'Brien, Stephen P. Mulligan, Neil E. Kay, Peter Hillmen...> ;Leukemia Research. 2020 Aug 11
• 101 citations
  Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
  John C. Byrd, Richard R. Furman, Steven Coutre, Ian W. Flinn, Jan A. Burger, Kristie A. Blum, Jeff P. Sharman, William G. Wierda, Weiqiang Zhao, Nyla A. Heerema, Ying ...> ;Clinical Cancer Research. 2020 Mar 24
• 17 citations
  Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib
  Melissa Hopper, Tarikere Gururaja, Taisei Kinoshita, James P. Dean, Ronald J. Hill, Ann Mongan> ;The Journal of Pharmacology and Experimental Therapeutics. 2020 Mar 1
• 274 citations
  Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
  Jan A. Burger, Paul M. Barr, Tadeusz Robak, Carolyn Owen, Paolo Ghia, Alessandra Tedeschi, Osnat Bairey, Peter Hillmen, Steven Coutre, Stephen Devereux, Sebastian Gros...> ;Leukemia. 2020 Mar 1
• 266 citations
  Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
  Talha Munir, Jennifer R. Brown, Susan O'Brien, Jacqueline C. Barrientos, Paul M. Barr, Nishitha Reddy, Steven Coutre, Constantine S. Tam, Stephen P. Mulligan, Ulrich J...> ;American Journal of Hematology. 2019 Dec 1
• 202 citations
  Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
  Ruben A. Mesa, Alessandro M. Vannucchi, Adam J. Mead, Miklos Egyed, Anita Szoke, Aleksandr Suvorov, János Jakucs, Andrew C. Perkins, Ritam Prasad, Jiri Mayer, Judit De...> ;The Lancet. Haematology. 2017 May 1
• On-target activity of neoadjuvant cixutumumab and combined androgen deprivation therapy for high-risk prostate cancer: A phase II trial.
  Dean JP, Montgomery RB, Wan J, Cohen P, Haugk K, Corman JM, Ellis WJ, Dalkin BL, Ludwig DL, Plymate SR> ;J Clin Oncol. 2011 Mar
• 22 citations
  Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma.
  David Belada, Pencho Georgiev, Shaker R. Dakhil, Lowell F Inhorn, David Andorsky, J. Thaddeus Beck, Donald Quick, Ruth Pettengell, Robert Daly, James P Dean, Mariya Pa...> ;Future Oncology. 2016 Apr 20
• 22 citations
  Response of the Insulin-Like Growth Factor (IGF) System to IGF-IR Inhibition and Androgen Deprivation in a Neoadjuvant Prostate Cancer Trial: Effects of Obesity and An...
  James P. Dean, Cynthia C. Sprenger, Junxiang Wan, Kathleen Haugk, William J. Ellis, Daniel W. Lin, John M. Corman, Bruce L. Dalkin, Elahe A. Mostaghel, Peter S. Nelson...> ;The Journal of Clinical Endocrinology and Metabolism. 2013 Mar 26
• Does chemotherapy have a role before hormone-resistant disease develops?
  James P. Dean, Celestia S. Higano> ;Current Urology Reports. 2009 Apr 18
• Profiling influences of senescent and aged fibroblasts on prostate carcinogenesis.
  Dean, J. P.,Nelson, P. S.> ;Br. J. Cancer. 2008 Jan 10
• 321 citations
  The Gene Expression Program of Prostate Fibroblast Senescence Modulates Neoplastic Epithelial Cell Proliferation through Paracrine Mechanisms
  Claes Bavik, Ilsa Coleman, James P. Dean, Beatrice S. Knudsen, Steven Plymate, Peter S. Nelson> ;Cancer Research. 2006 Jan 15
• Expression of MFA1 and STE6 is sufficient for mating type-independent secretion of yeast a-factor, but not mating competence.
  Gary E. Quinby, James P. Dean, Robert J. Deschenes> ;Current Genetics. 1999 Feb 1
• Join now to see all

Abstracts/Posters

• Using Ibrutinib in Earlier Lines of Treatment Results in Better Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  James P. Dean, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019